

2019 Taipei International Breast Cancer Symposium			
2F, HuaNan Bank International Convention Center		Sat., November 2, 2019	
Time	Topic	Speaker	Moderator
08:25-08:30	Opening Remarks	Ling-Ming Tseng	
08:30-08:40		Shih-Chung Chen	
08:40-09:10	Breast Cancer Screening in Taiwan: An International Perspective	Hsiu-Hsi Chen	James Giu-Cheng Hsu Jane Wang
Refining Immunotherapy Strategies in Breast Cancer			
09:10-09:40	Recent Advances and Future Perspectives of Immunotherapy in TNBC	Charles E. Geyer	Jyh-Cherng Yu Kuo-Hsiu Liao
09:40-10:10	Current Immunotherapy Trends and Breakthroughs for Advanced TNBC	Ming-Shen Dai	Chen-Hsiang Chang
10:10-10:30	Coffee Break		
10:30-11:00	Chemotherapy as Partner of Immunotherapy for Advanced Her2 Negative Breast Cancer	Takashi Ishikawa	Ming-Feng Hou
11:00-11:30	Prevention & Management of Hepatitis B Virus Reactivation in BC Patients Receiving Antineoplastic Agents	Ta-Chung Chao	Tsu-Yi Chao
11:30-12:00	Panel Discussion (1)	Wen-Ling Kuo Dwan-Ying Chang Woo Young Sun Charles E. Geyer Ming-Shen Dai Takashi Ishikawa Ta-Chung Chao	Hwei-Chung Wang Mei-Ching Liu
12:00-12:30	Boosting Anti-Tumor Immunity and Immunotherapy Response in Breast Cancers	Di-Hua Yu	King-Jen Chang
12:30-13:10	Luncheon Symposium Genomic Landscape of Breast Cancer in Taiwan	Chien-Feng Li	Fang-Ming Chen
13:10-13:20	Break		
The Promise of Precision Oncology in Breast Cancer			
13:20-13:50	Plenary Lecture Current and Future Direction of NSABP	Charles E. Geyer	Ling-Ming Tseng
13:50-14:20	Decoding Breast Cancer Brain Metastasis and Devising Effective Therapies	Di-Hua Yu	Chien-Liang Liu Huan-Ming Hsu
14:20-14:50	The Role of Tyrosine Kinase Inhibitors and Other Molecular Targeted Agents in the Treatment of HER2 Positive Breast Cancer	Ingrid Mayer	Yen-Shen Lu Yi-Fang Tsai
14:50-15:20	Clinical Utility of Gene Expression Signature in EBC	Marc Thill	Chii-Ming Chen Shih-Hsin Tu
15:20-15:40	Coffee Break		
15:40-16:10	Systemic Therapy of HER2-Positive Early Breast Cancer	Charles E. Geyer	Chiun-Sheng Huang
16:10-16:40	How PARP Inhibitor Benefit Patients Further: for Now and the Future	Tan Jing Ying Tira	Kun-Ming Rau Liang-Chih Liu
16:40-17:10	Biosimilar in Germany: Current State of Play	Marc Thill	Shyr-Ming Sheen-Chen
17:10-17:40	Panel Discussion (2)	Chieh-Han Chuang Chi-Cheng Huang Jun Won Min Di-Hua Yu Ingrid Mayer Marc Thill Charles E. Geyer Tan Jing Ying Tira	Shin-Cheh Chen Ching-Hung Lin

09:30-11:30 sponsored by Roche, MSD, Eisai, BMS  
14:20-14:50 sponsored by CANbridge

Luncheon Symposium sponsored by ACTG  
15:40-17:10 sponsored by Roche, AZ, Amgen

# 2019 Taipei International Breast Cancer Symposium

2F, HuaNan Bank International Convention Center

Sun., November 3, 2019

Time	Topic	Speaker	Moderator
08:00-08:30	<b>Breakfast Symposium</b> Management of Febrile Neutropenia in Breast Cancer Patients with Neoadjuvant and Adjuvant Chemotherapy	Takashi Ishikawa	Hong-Tai Chang
Therapeutic Deep-Dive into HR+ Breast Cancer			
08:45-09:15	Optimizing Endocrine Treatment in HR+HER2- Metastatic Breast Cancer	Ming-Shen Dai	Hwei-Chung Wang
09:15-09:45	Beyond Toxicity, Seek Differences in Similarities Among 3 CDK4 & 6 Inhibitors	Ingrid Mayer	Ming-Feng Hou Ming-Hsin Yeh
09:45-10:15	Improvement of Overall Survival with CDk4/6 Inhibitors in HR+ HER2- Advanced Breast Cancer	Christian Jackisch	Hsien-Kun Chang Ming-Yang Wang
10:15-10:35	Coffee Break		
10:35-11:05	Precision Medicine in the Treatment of HR+ Advanced Breast Cancer	Christian Jackisch	Tsu-Yi Chao Kuo-Ting Lee
11:05-11:35	The Evolving Landscape of HR Positive Metastatic Breast Cancer: Past, Present and Future	Shaheena Dawood	Ling-Ming Tseng
11:35-12:05	<b>Panel Discussion (3)</b>	Yuan-Ching Chang Wei-Pang Chung Ming-Shen Dai Ingrid Mayer Christian Jackisch Shaheena Dawood	Yen-Shen Lu Lo Chiao
12:05-12:45	<b>Luncheon Symposium</b> Flexible Chemotherapy Strategies for Long-Term Disease Control in Metastatic Breast Cancer	Chun-Yu Liu	Hsien-Kun Chang
12:45-13:00	Break		
Leveraging Breast Cancer Locoregional Management			
13:00-13:30	Management of Low Risk-DCIS	Florian Fitzal	Dar-Ren Chen
13:30-14:00	When Can We Omit Breast/Axillar Surgery	John Benson	Fiona Tsui-Fen Cheng Chao-Ming Hung
14:00-14:20	Coffee Break		
14:20-14:50	Radiotherapy after pCR Following Primary Systemic Therapy	Philip M.P. Poortmans	Tsen-Long Yang Hsien-Tang Yeh
14:50-15:20	Surgical Treatment of Multiple Ipsilateral Breast Cancers	John Benson	Shou-Tung Chen Hung-Wen Lai
15:20-15:50	IORT, Hypofraction Radiation, Partial Breast Radiation, or no Radiation	Philip M.P. Poortmans	Yao-Jen Chang Dah-Cherng Yeh
15:50-16:20	Oncoplastic Surgery in the era of Precisional Medicine	Florian Fitzal	Shin-Cheh Chen Yao-Lung Kuo
16:20-16:50	<b>Panel Discussion (4)</b>	Hisamitsu Zaha Chia-Ming Hsieh Fang-Ming Chen Frank Fu Ou-Yang Wen-Hung Kuo Shih-Che Shen Florian Fitzal John Benson Philip M.P. Poortmans	Chiun-Sheng Huang Dar-Ren Chen
16:50-17:00	Closing	Ling-Ming Tseng	

08:00-11:35 sponsored by Kyowakirin, Lilly, Novartis, Pfizer

Luncheon Symposium sponsored by TTY